JP2011525902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525902A5 JP2011525902A5 JP2011515663A JP2011515663A JP2011525902A5 JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5 JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011515663 A JP2011515663 A JP 2011515663A JP 2011525902 A5 JP2011525902 A5 JP 2011525902A5
- Authority
- JP
- Japan
- Prior art keywords
- pathogen
- immune response
- subject
- composition
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13314008P | 2008-06-25 | 2008-06-25 | |
| US61/133,140 | 2008-06-25 | ||
| PCT/IB2009/006260 WO2009156852A1 (en) | 2008-06-25 | 2009-06-25 | Rapid responses to delayed booster immunisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525902A JP2011525902A (ja) | 2011-09-29 |
| JP2011525902A5 true JP2011525902A5 (enExample) | 2012-08-09 |
| JP5712126B2 JP5712126B2 (ja) | 2015-05-07 |
Family
ID=41171092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515663A Expired - Fee Related JP5712126B2 (ja) | 2008-06-25 | 2009-06-25 | 遅延型追加刺激免疫処置に対する迅速な応答 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9421251B2 (enExample) |
| EP (1) | EP2310045A1 (enExample) |
| JP (1) | JP5712126B2 (enExample) |
| CA (1) | CA2729248A1 (enExample) |
| WO (1) | WO2009156852A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2804492A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| JP2013537518A (ja) | 2010-07-06 | 2013-10-03 | ノバルティス アーゲー | ＲＮＡ送達に有利なｐＫａ値を有する脂質を含むリポソーム |
| FI4066857T3 (fi) | 2010-08-31 | 2023-03-20 | Glaxosmithkline Biologicals Sa | Pegyloituja liposomeja immunogeeniä koodaavan rna:n kuljettamiseksi |
| RU2597974C2 (ru) | 2010-10-11 | 2016-09-20 | Новартис Аг | Платформы доставки антигенов |
| CA2832712C (en) | 2011-04-22 | 2018-08-28 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| JP2014520807A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | 免疫原性組成物およびその使用 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| US20030072764A1 (en) * | 2001-04-05 | 2003-04-17 | O'hagan Derek | Mucosal boosting following parenteral priming |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| TWI365074B (en) | 2004-10-07 | 2012-06-01 | Wyeth Corp | Multivalent avian influenza vaccines |
| US20100015211A1 (en) | 2004-11-01 | 2010-01-21 | Barnett Susan W | Combination Approaches For Generating Immune Responses |
| AR052625A1 (es) | 2005-03-23 | 2007-03-21 | Glaxosmithkline Biolog Sa | Nueva composicion |
| JP2009514850A (ja) * | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
| CA2628379A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Adminstration routes for priming/boosting with influenza vaccines |
| US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
| EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
| US20080014217A1 (en) | 2006-07-17 | 2008-01-17 | Emmanuel Jules Hanon | Influenza vaccine |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
-
2009
- 2009-06-25 WO PCT/IB2009/006260 patent/WO2009156852A1/en not_active Ceased
- 2009-06-25 EP EP09769663A patent/EP2310045A1/en not_active Withdrawn
- 2009-06-25 US US12/999,848 patent/US9421251B2/en not_active Expired - Fee Related
- 2009-06-25 JP JP2011515663A patent/JP5712126B2/ja not_active Expired - Fee Related
- 2009-06-25 CA CA2729248A patent/CA2729248A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525902A5 (enExample) | ||
| Kim et al. | Influenza vaccines: Past, present, and future | |
| JP6308500B2 (ja) | 強化された免疫賦活化剤 | |
| Alving et al. | Adjuvants for human vaccines | |
| Jabbal-Gill | Nasal vaccine innovation | |
| Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
| Levitz et al. | Beyond empiricism: informing vaccine development through innate immunity research | |
| Mori et al. | The vaccine adjuvant alum inhibits IL‐12 by promoting PI 3 kinase signaling while chitosan does not inhibit IL‐12 and enhances T h1 and T h17 responses | |
| Skene et al. | Saponin-adjuvanted particulate vaccines for clinical use | |
| Yusuf et al. | Current prospects and future challenges for nasal vaccine delivery | |
| Riese et al. | Intranasal formulations: promising strategy to deliver vaccines | |
| Pellegrini et al. | MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database | |
| Tetsutani et al. | Adjuvants in influenza vaccines | |
| de Haan et al. | Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration | |
| CN109364244B (zh) | 黏膜佐剂和递送系统 | |
| Dehghan et al. | Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants | |
| JP2003523310A (ja) | 新規インフルエンザウイルスワクチン組成物 | |
| TW200722101A (en) | Novel composition | |
| Cheong et al. | Epigallocatechin-3-gallate as a novel vaccine adjuvant | |
| Jones et al. | Protollin™: a novel adjuvant for intranasal vaccines | |
| Chua et al. | Opinion: making inactivated and subunit-based vaccines work | |
| JP2015529677A5 (enExample) | ||
| de Veer et al. | New developments in vaccine research—unveiling the secret of vaccine adjuvants | |
| Suresh et al. | Evaluation of mucosal adjuvants to chitosan-nanoparticle-based oral subunit vaccine for controlling salmonellosis in broilers | |
| Li et al. | Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications |